MDRNA has presented new in vivo data demonstrating continued progress in the advancement of its oncology program. The company reported that MDRNA’s UsiRNAs, delivered by its DiLA2 platform, down-regulated a previously non-druggable target with subsequent reductions in tumor growth in models of liver and bladder cancer via both systemic and local delivery.
The company said that MDRNA has demonstrated delivery of a UsiRNA targeting survivin, a protein involved in mitotic progression and inhibition of apoptosis, via intravenous administration using its DiLA2 liposome formulation in two liver cancer models.
The company has reported data from an orthotopic bladder cancer model in which localised application (intravesical dosing) of the survivin UsiRNA to a bladder tumor was performed using a DiLA2 liposome formulation.
Michael French, president and CEO of MDRNA, said: “We have always maintained that our RNAi discovery engine can generate novel compounds with broad therapeutic applicability. These data are a powerful indicator of the value and strength of that drug discovery platform and represents a significant step in the advancement of our product pipeline. Moreover, we now have evidence illustrating the potential role of RNAi-based therapeutics in down-regulating typically non-druggable targets.”
MDRNA is a biotechnology company focused on the development and commercialisation of therapeutic products based on RNA interference (RNAi).